Neogap is granted Australian patent for innovative method of MS treatment and diagnosis
The Swedish biotechnology company Neogap Therapeutics, which develops personalised immunotherapy, has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens Neogap's strategic intellectual property portfolio and marks an important step in the company's efforts to develop groundbreaking treatments for autoimmune diseases such as MS.The patent covers a tolerogenic treatment method for multiple sclerosis (MS). The method utilises specially designed molecules to influence the